sdbn.org

BioSpace, News, Syndication »

Orexigen Therapeutics, Inc. Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
Posted by BioSpace.com Featured News July 29th, 2010 .
No Comments

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration... More...

BioSpace, News, Syndication »

Cadence Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2010 Financial Results on August 5, 2010
Posted by BioSpace.com Featured News July 29th, 2010 .
No Comments

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its second quarter ended June 30, 2010 financial... More...

BioSpace, News, Syndication »

Gen-Probe Incorporated Reports Financial Results for the Second Quarter of 2010
Posted by BioSpace.com Featured News July 29th, 2010 .
No Comments

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) today reported financial results for the second quarter of 2010, highlighted by 14% growth in product sales, 15% growth in total revenues, and 16% growth in non-GAAP earnings per share (EPS).

"Gen-Probe's second quarter financial results demonstrate our ability to drive growth... More...

BioSpace, News, Syndication »

Genoptix, Inc. Reports Operating Results for the Second Quarter 2010
Posted by BioSpace.com Featured News July 29th, 2010 .
No Comments

CARLSBAD, Calif., July 29 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today reported revenue of $50.9 million for the second quarter of 2010. Net income was $5.6 million or $0.31 per diluted share for the quarter. ... More...

BioSpace, News, Syndication »

Halozyme Therapeutics, Inc. Announces Second Quarter 2010 Financial Results Conference Call on August 6, 2010
Posted by BioSpace.com Featured News July 29th, 2010 .
No Comments

SAN DIEGO, July 30/PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced it plans to report second quarter 2010 financial results on Friday, August... More...

BioSpace, News, Syndication »

Sequenom Inc. Announces Date of Second Quarter 2010 Financial Results and Conference Call
Posted by BioSpace.com Featured News July 29th, 2010 .
No Comments

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM), will report second quarter 2010 financial results after market close on Thursday August 5, 2010. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time... More...

BioSpace, News, Syndication »

Orexigen Therapeutics, Inc. Obesity Pill Shows Promise in Phase III Study; Stock Rises 11.37% at 10:17AM EDT
Posted by BioSpace.com Featured News July 29th, 2010 .
No Comments

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration... More...

BioSpace, News, Syndication »

Lpath, Inc. Receives $3 Million Grant From the National Eye Institute
Posted by BioSpace.com Featured News July 29th, 2010 .
No Comments